Harbor Capital Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Harbor Capital Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,068	Closed	-$726K	–	1235
2026 Q1	$726K	Sell	15,068 -6,475	-30%	-$287K	0.06%	394
2025 Q4	$889K	Buy	21,543 +843	+4%	+$33.8K	0.07%	353
2025 Q3	$804K	Sell	20,700 -50,226	-71%	-$1.63M	0.06%	370
2025 Q2	$1.96M	Sell	70,926 -6,796	-9%	-$173K	0.08%	302
2025 Q1	$1.73M	Sell	77,722 -20,371	-21%	-$419K	0.08%	319
2024 Q4	$1.94M	Buy	98,093 +550	+0.6%	+$12.6K	0.08%	298
2024 Q3	$2.44M	Buy	+97,543	New	+$2.38M	0.11%	267
2024 Q2	–	Sell	-13,142	Closed	-$259K	–	749
2024 Q1	$259K	Buy	+13,142	New	+$257K	0.03%	551

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Harbor Capital Advisors's KNSA Position: Q2 2026 in Review

Harbor Capital Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 15,068 shares — an estimated $726K sold.

Harbor Capital Advisors first reported a position in KNSA in Q1 2024 and held it in 8 quarters. The position peaked at $2.44M in Q3 2024. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Harbor Capital Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Harbor Capital Advisors sold 15,068 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $726K.
Harbor Capital Advisors first reported a position in Kiniksa Pharmaceuticals in Q1 2024 and held it in 8 quarters.
Harbor Capital Advisors's Kiniksa Pharmaceuticals position peaked at $2.44M in Q3 2024.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.